Mycobacterium szulgai Lung Disease or Breast Cancer Relapse—Case Report

Cancers are one of the risk factors of non-tuberculous mycobacterial (NTM) lung disease. The majority of data in this group of patients concern infections caused by Mycobacterium avium—the most prevalent NTM species worldwide. In contrast, limited information can be found regarding the uncommon NTM such as Mycobacterium szulgai. We present the case of M. szulgai lung disease in a patient with a history of breast cancer. Coexistence of NTM lung disease and breast cancer lung metastasis as well as primary lung cancer was suspected. Finally, neoplastic disease was ruled out based on negative results of endobronchial biopsy and negative tumor markers for lung and breast cancer. M. szulgai lung disease was successfully treated with rifampicin, ethambutol and clarithromycin.

Download Full-text

Association of a history of autoimmunity or hypersensitivity with overall survival in breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.1594 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 1594-1594

Author(s):

Hakan Lars Olsson ◽

Ulrika Kogler ◽

Rickard Einefors ◽

Carolina Ellberg

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Malignant Melanoma ◽

Autoimmune Disease ◽

Reference Group ◽

Menopausal Status ◽

Young Patients ◽

P Value ◽

History Of ◽

Negative Tumor

1594 Background: Antibody therapy of malignant melanoma with ipilimumab is associated with the development of an autoimmune disease. The aim was to investigate if preexisting autoimmune disorders or hypersensitivities, similar to the side effects of immunotherapy in malignant melanoma, gave a better overall survival for breast cancer (BC) patients, compared with patients without these disorders. Methods: A consecutive clinical material consisting of 1,705 breast cancer patients diagnosed between 1980 and 2010 was used. The patients were grouped according to preexisting autoimmune disease or hypersensitivities. The remaining BC patients were used as a reference group. All analyses were adjusted for age at diagnosis, T, N, M-status of the tumor, and ever-use of HRT simultaneously. A p value of less than 0.05 was considered significant. Results: One hundred and twenty-five (7.3%) patients had a history of autoimmunity and 72 (4.2%) patients had a history of hypersensitivity prior to BC diagnosis. Our main finding was that BC patients with a preexisting autoimmune disease or hypersensitivities with ER-negative tumors had a longer overall survival compared to patients without, HR 0.55, 95% CI 0.31-0.97. The risk was specifically low in BC patients with hypersensitivity and ER-negative tumors, HR 0.39, 95% CI 0.16-0.96. The risk was nonsignificantly lower in the autoimmune group, HR 0.78, 95% CI 0.37-1.61. Stratifying both on ER-status and menopausal status, similar results were seen in premenopausal BC patients with hypersensitivity. Postmenopausal BC patients with an ER-negative tumor and an autoimmune disease had a longer nonsignificant overall survival, HR 0.3, 95% CI 0.07-1.26. Conclusions: BC patients with an ER-negative tumor and/or diagnosed before menopause had a longer overall survival when previously diagnosed with hypersensitivity. For BC patients with an autoimmune disease, the prognostic benefit was seen when diagnosed postmenopausally with an ER-negative BC. Preexisting or induced autoimmunity or hypersensitivity may prolong life in breast cancer especially in young patients and those with ER-negative tumors.

Download Full-text

Lymphangioleiomyomatosis

Journal of Clinical Images and Medical Case Reports ◽

10.52768/2766-7820/1378 ◽

2021 ◽

Vol 2 (5) ◽

Author(s):

Klein Dantis ◽

◽

Ranganath TG ◽

Keyword(s):

Interstitial Lung Disease ◽

Lung Disease ◽

Gold Standard ◽

Pulmonary Rehabilitation ◽

Histopathological Diagnosis ◽

Neoplastic Disease ◽

European Respiratory Society ◽

Free Survival ◽

Bronchodilator Therapy ◽

History Of

Lymphangioleiomyomatosis (LAM) is a rare systematic neoplastic disease exclusively seen in middle-aged women with an incidence of 5-9 per million. They can occur sporadically or in association with tuberous sclerosis. Histopathological diagnosis is the gold standard. Median transplant-free survival from the time of diagnosis is 23 years. We here by present premenstrual female with history of recurrent dyspnea with differential diagnosis for various interstitial lung disease diagnosed to have LAM. She was managed with bronchodilator therapy and pulmonary rehabilitation as per European respiratory society guidelines. Keywords: lymphangioleiomyomatosis; interstitial lung disease; uniportal VATS; histopathology

Download Full-text

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review

Case Reports in Oncology ◽

10.1159/000491574 ◽

2018 ◽

Vol 11 (2) ◽

pp. 527-533 ◽

Cited By ~ 4

Author(s):

Heidi Egloff ◽

Kelley M. Kidwell ◽

Anne Schott

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Lung Disease ◽

Potential Risk ◽

Pulmonary Toxicity ◽

Clinical Symptoms ◽

Pulmonary Metastases ◽

Sample Population ◽

Potential Risk Factors ◽

History Of

Purpose: T-DM1 is an antibody drug conjugate with proven efficacy in metastatic breast cancer for progressive disease refractory to trastuzumab. Drug-induced pneumonitis is a rare serious potential adverse effect. The purpose of this review was to estimate the incidence of pulmonary toxicity at our institution. Methods: A retrospective analysis of electronic medical record data inclusive of all women and men aged 18 years and older treated with T-DM1 at out institution was undertaken. The records were reviewed for clinical symptoms and/or radiographic evidence concerning for pneumonitis. We identified variables of interest with regard to potential risk factors for toxicity. Results: A total of 50 patients were included, 6 (12%) of whom had radiographic and/or clinical symptoms concerning for T-DM1-induced pneumonitis. All 6 patients had metastatic or unresectable breast cancer. Of the 6 patients, 5 (83%) had suspected pulmonary metastases, 1 (17%) had a history of underlying lung disease, and 5 (83%) had a history of prior taxane therapy. Pulmonary metastases (p = 0.38), the median number of treatment cycles (p = 0.29), prior taxane therapy (p = 0.99), underlying lung disease (p = 0.99), and hormone receptor positivity (p = 0.66) did not have any statistical significance for an association with pneumonitis. Conclusion: Pneumonitis is a recognized toxic effect of T-DM1. While our sample size was small, the number of events was higher than described in the literature, which may be an artifact of referral bias. Future studies with a larger sample population may detect potential risk factors for toxicity.

Download Full-text